BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Goyal L, Zheng H, Yurgelun MB, Abrams TA, Allen JN, Cleary JM, Knowles M, Regan E, Reardon A, Khachatryan A, Jain RK, Nardi V, Borger DR, Duda DG, Zhu AX. A phase 2 and biomarker study of cabozantinib in patients with advanced cholangiocarcinoma. Cancer 2017;123:1979-88. [PMID: 28192597 DOI: 10.1002/cncr.30571] [Cited by in Crossref: 54] [Cited by in F6Publishing: 47] [Article Influence: 10.8] [Reference Citation Analysis]
Number Citing Articles
1 Abboud HS, Camuzi D, Rapozo DC, Fernandes PV, Nicolau-Neto P, Guaraldi S, Simão TA, Ribeiro Pinto LF, Gonzaga IM, Soares-Lima SC. MET overexpression and intratumor heterogeneity in esophageal squamous cell carcinoma. Braz J Med Biol Res 2021;54:e10877. [PMID: 34037097 DOI: 10.1590/1414-431X2020e10877] [Reference Citation Analysis]
2 Morizane C, Ueno M, Ikeda M, Okusaka T, Ishii H, Furuse J. New developments in systemic therapy for advanced biliary tract cancer. Japanese Journal of Clinical Oncology 2018;48:703-11. [DOI: 10.1093/jjco/hyy082] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 7.3] [Reference Citation Analysis]
3 Ho WJ, Zhu Q, Durham J, Popovic A, Xavier S, Leatherman J, Mohan A, Mo G, Zhang S, Gross N, Charmsaz S, Lin D, Quong D, Wilt B, Kamel IR, Weiss M, Philosophe B, Burkhart R, Burns WR, Shubert C, Ejaz A, He J, Deshpande A, Danilova L, Stein-O'Brien G, Sugar EA, Laheru DA, Anders RA, Fertig EJ, Jaffee EM, Yarchoan M. Neoadjuvant Cabozantinib and Nivolumab Converts Locally Advanced HCC into Resectable Disease with Enhanced Antitumor Immunity. Nat Cancer 2021;2:891-903. [PMID: 34796337 DOI: 10.1038/s43018-021-00234-4] [Cited by in Crossref: 3] [Article Influence: 3.0] [Reference Citation Analysis]
4 Moosavi F, Giovannetti E, Saso L, Firuzi O. HGF/MET pathway aberrations as diagnostic, prognostic, and predictive biomarkers in human cancers. Crit Rev Clin Lab Sci 2019;56:533-66. [PMID: 31512514 DOI: 10.1080/10408363.2019.1653821] [Cited by in Crossref: 33] [Cited by in F6Publishing: 34] [Article Influence: 11.0] [Reference Citation Analysis]
5 Chen C, Nelson LJ, Ávila MA, Cubero FJ. Mitogen-Activated Protein Kinases (MAPKs) and Cholangiocarcinoma: The Missing Link. Cells 2019;8:E1172. [PMID: 31569444 DOI: 10.3390/cells8101172] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
6 Zhang R, Puzzoni M, Mariani S, Zheng Y, Liscia N, Guo Y, Donisi C, Liu Y, Impera V, Fang W, Scartozzi M. Emerging treatment evolutions and integrated molecular characteristics of biliary tract cancers. Cancer Sci 2021. [PMID: 34534382 DOI: 10.1111/cas.15139] [Reference Citation Analysis]
7 Kam AE, Masood A, Shroff RT. Current and emerging therapies for advanced biliary tract cancers. Lancet Gastroenterol Hepatol 2021;6:956-69. [PMID: 34626563 DOI: 10.1016/S2468-1253(21)00171-0] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
8 Ejaz A, Cloyd JM, Pawlik TM. Advances in the Diagnosis and Treatment of Patients with Intrahepatic Cholangiocarcinoma. Ann Surg Oncol. 2020;27:552-560. [PMID: 31555936 DOI: 10.1245/s10434-019-07873-z] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
9 Chakrabarti S, Kamgar M, Mahipal A. Targeted Therapies in Advanced Biliary Tract Cancer: An Evolving Paradigm.Cancers (Basel). 2020;12. [PMID: 32722188 DOI: 10.3390/cancers12082039] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 10.5] [Reference Citation Analysis]
10 B Peters ML, Miksad RA. Cabozantinib in the treatment of hepatocellular carcinoma. Future Oncology 2017;13:1915-29. [DOI: 10.2217/fon-2017-0169] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
11 Adeva J, Sangro B, Salati M, Edeline J, La Casta A, Bittoni A, Berardi R, Bruix J, Valle JW. Medical treatment for cholangiocarcinoma. Liver Int 2019;39:123-42. [DOI: 10.1111/liv.14100] [Cited by in Crossref: 33] [Cited by in F6Publishing: 30] [Article Influence: 11.0] [Reference Citation Analysis]
12 van Boxtel W, Uijen MJ, Krens SD, Dijkema T, Willems SM, Jonker MA, Pegge SA, van Engen-van Grunsven AC, van Herpen CM. Excessive toxicity of cabozantinib in a phase II study in patients with recurrent and/or metastatic salivary gland cancer. European Journal of Cancer 2022;161:128-37. [DOI: 10.1016/j.ejca.2021.10.033] [Reference Citation Analysis]
13 Høgdall D, Lewinska M, Andersen JB. Desmoplastic Tumor Microenvironment and Immunotherapy in Cholangiocarcinoma. Trends Cancer 2018;4:239-55. [PMID: 29506673 DOI: 10.1016/j.trecan.2018.01.007] [Cited by in Crossref: 40] [Cited by in F6Publishing: 38] [Article Influence: 10.0] [Reference Citation Analysis]
14 Pellino A, Loupakis F, Cadamuro M, Dadduzio V, Fassan M, Guido M, Cillo U, Indraccolo S, Fabris L. Precision medicine in cholangiocarcinoma. Transl Gastroenterol Hepatol 2018;3:40. [PMID: 30148225 DOI: 10.21037/tgh.2018.07.02] [Cited by in Crossref: 27] [Cited by in F6Publishing: 28] [Article Influence: 6.8] [Reference Citation Analysis]
15 Wang L, Zhu H, Zhao Y, Pan Q, Mao A, Zhu W, Zhang N, Lin Z, Zhou J, Wang Y, Zhang Y, Wang M, Feng Y, He X, Xu W, Wang L. Comprehensive molecular profiling of intrahepatic cholangiocarcinoma in the Chinese population and therapeutic experience. J Transl Med 2020;18:273. [PMID: 32631434 DOI: 10.1186/s12967-020-02437-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
16 Yin J, Liu H, Huan L, Song S, Han L, Ren F, Zhang Z, Zang Z, Zhang J, Wang S. Role of miR-128 in hypertension-induced myocardial injury. Exp Ther Med 2017;14:2751-6. [PMID: 28928797 DOI: 10.3892/etm.2017.4886] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
17 Chiang NJ, Chen LT, Shan YS, Yeh CN, Chen MH. Development of Possible Next Line of Systemic Therapies for Gemcitabine-Resistant Biliary Tract Cancers: A Perspective from Clinical Trials. Biomolecules 2021;11:97. [PMID: 33451059 DOI: 10.3390/biom11010097] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
18 Chen WX, Li GX, Hu ZN, Zhu P, Zhang BX, Ding ZY. Significant response to anti-PD-1 based immunotherapy plus lenvatinib for recurrent intrahepatic cholangiocarcinoma with bone metastasis: A case report and literature review. Medicine (Baltimore) 2019;98:e17832. [PMID: 31702638 DOI: 10.1097/MD.0000000000017832] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 6.0] [Reference Citation Analysis]
19 Palmieri LJ, Lavolé J, Dermine S, Brezault C, Dhooge M, Barré A, Chaussade S, Coriat R. The choice for the optimal therapy in advanced biliary tract cancers: Chemotherapy, targeted therapies or immunotherapy. Pharmacol Ther 2020;210:107517. [PMID: 32109491 DOI: 10.1016/j.pharmthera.2020.107517] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
20 Smulever A, Abelleira E, Bueno F, Pitoia F. Thyroid cancer in the Era of COVID-19. Endocrine 2020;70:1-5. [PMID: 32754886 DOI: 10.1007/s12020-020-02439-6] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
21 Ioffe D, Phull P, Dotan E. Optimal Management of Patients with Advanced or Metastatic Cholangiocarcinoma: An Evidence-Based Review. Cancer Manag Res 2021;13:8085-98. [PMID: 34737637 DOI: 10.2147/CMAR.S276104] [Reference Citation Analysis]
22 Ntanasis-Stathopoulos I, Tsilimigras DI, Gavriatopoulou M, Schizas D, Pawlik TM. Cholangiocarcinoma: investigations into pathway-targeted therapies. Expert Rev Anticancer Ther 2020;20:765-73. [PMID: 32757962 DOI: 10.1080/14737140.2020.1807333] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
23 Kim R, Chiorean EG, Amin M, Rocha-Lima CMS, Gandhi J, Harris WP, Song T, Portnoy D. Phase 2 study of combination SPI-1620 with docetaxel as second-line advanced biliary tract cancer treatment. Br J Cancer 2017;117:189-94. [PMID: 28632730 DOI: 10.1038/bjc.2017.160] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
24 Okano N, Furuse J, Ueno M, Morizane C, Yamanaka T, Ojima H, Ozaka M, Sasaki M, Takahara N, Nakai Y, Kobayashi S, Morimoto M, Hosoi H, Maeno S, Nagashima F, Ikeda M, Okusaka T. Multicenter Phase II Trial of Axitinib Monotherapy for Gemcitabine-Based Chemotherapy Refractory Advanced Biliary Tract Cancer (AX-BC Study). Oncologist 2021;26:97-e201. [PMID: 33010112 DOI: 10.1002/onco.13547] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
25 Buckholz AP, Brown RS Jr. Cholangiocarcinoma: Diagnosis and Management. Clin Liver Dis 2020;24:421-36. [PMID: 32620281 DOI: 10.1016/j.cld.2020.04.005] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
26 Yarlagadda B, Kamatham V, Ritter A, Shahjehan F, Kasi PM. Trastuzumab and pertuzumab in circulating tumor DNA ERBB2-amplified HER2-positive refractory cholangiocarcinoma.NPJ Precis Oncol. 2019;3:19. [PMID: 31453370 DOI: 10.1038/s41698-019-0091-4] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 4.0] [Reference Citation Analysis]
27 Dhani NC, Hirte HW, Wang L, Burnier JV, Jain A, Butler MO, Welch S, Fleming GF, Hurteau J, Matsuo K, Matei D, Jimenez W, Johnston C, Cristea M, Tonkin K, Ghatage P, Lheureux S, Mehta A, Quintos J, Tan Q, Kamel-Reid S, Ludkovski O, Tsao MS, Wright JJ, Oza AM. Phase II Trial of Cabozantinib in Recurrent/Metastatic Endometrial Cancer: A Study of the Princess Margaret, Chicago, and California Consortia (NCI9322/PHL86). Clin Cancer Res 2020;26:2477-86. [PMID: 31992589 DOI: 10.1158/1078-0432.CCR-19-2576] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
28 Huang P, Zhou Y, Chen Y. Significant Response to Camrelizumab Plus Targeted Drugs in Recurrent Intrahepatic Cholangiocarcinoma: a Case Report and Literature Review. J Gastrointest Cancer 2021. [PMID: 34312770 DOI: 10.1007/s12029-021-00637-7] [Reference Citation Analysis]
29 Xie C, McGrath NA, Monge Bonilla C, Fu J. Systemic treatment options for advanced biliary tract carcinoma. J Gastroenterol 2020;55:944-57. [PMID: 32748173 DOI: 10.1007/s00535-020-01712-9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
30 Bekaii-Saab TS, Valle JW, Van Cutsem E, Rimassa L, Furuse J, Ioka T, Melisi D, Macarulla T, Bridgewater J, Wasan H, Borad MJ, Abou-Alfa GK, Jiang P, Lihou CF, Zhen H, Asatiani E, Féliz L, Vogel A. FIGHT-302: first-line pemigatinib vs gemcitabine plus cisplatin for advanced cholangiocarcinoma with FGFR2 rearrangements. Future Oncol 2020;16:2385-99. [PMID: 32677452 DOI: 10.2217/fon-2020-0429] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 6.5] [Reference Citation Analysis]
31 Tsimafeyeu I, Temper M. Cholangiocarcinoma: An Emerging Target for Molecular Therapy. Gastrointest Tumors 2021;8:153-8. [PMID: 34722468 DOI: 10.1159/000517258] [Reference Citation Analysis]
32 Rimassa L, Personeni N, Czauderna C, Foerster F, Galle P. Systemic treatment of HCC in special populations. J Hepatol 2021;74:931-43. [PMID: 33248171 DOI: 10.1016/j.jhep.2020.11.026] [Cited by in Crossref: 6] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
33 Sutherland M, Ahmed O, Zaidi A, Ahmed S. Current progress in systemic therapy for biliary tract cancers. J Hepatobiliary Pancreat Sci 2021. [PMID: 33735541 DOI: 10.1002/jhbp.939] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
34 Rizvi S, Khan SA, Hallemeier CL, Kelley RK, Gores GJ. Cholangiocarcinoma - evolving concepts and therapeutic strategies. Nat Rev Clin Oncol. 2018;15:95-111. [PMID: 28994423 DOI: 10.1038/nrclinonc.2017.157] [Cited by in Crossref: 401] [Cited by in F6Publishing: 382] [Article Influence: 80.2] [Reference Citation Analysis]
35 Rabinowits G, Lezcano C, Catalano PJ, McHugh P, Becker H, Reilly MM, Huang J, Tyagi A, Thakuria M, Bresler SC, Sholl LM, Shapiro GI, Haddad R, DeCaprio JA. Cabozantinib in Patients with Advanced Merkel Cell Carcinoma. Oncologist 2018;23:814-21. [PMID: 29445030 DOI: 10.1634/theoncologist.2017-0552] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 4.0] [Reference Citation Analysis]
36 Lin J, Cao Y, Yang X, Li G, Shi Y, Wang D, Long J, Song Y, Mao J, Xie F, Bai Y, Zhang L, Yang X, Wan X, Wang A, Guan M, Zhao L, Hu K, Pan J, Huo L, Lu X, Mao Y, Sang X, Zhang H, Wang K, Wang X, Zhao H. Mutational spectrum and precision oncology for biliary tract carcinoma. Theranostics 2021;11:4585-98. [PMID: 33754015 DOI: 10.7150/thno.56539] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
37 Guo R, Luo J, Chang J, Rekhtman N, Arcila M, Drilon A. MET-dependent solid tumours - molecular diagnosis and targeted therapy. Nat Rev Clin Oncol 2020;17:569-87. [PMID: 32514147 DOI: 10.1038/s41571-020-0377-z] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 12.5] [Reference Citation Analysis]
38 Ghidini M, Pizzo C, Botticelli A, Hahne JC, Passalacqua R, Tomasello G, Petrelli F. Biliary tract cancer: current challenges and future prospects. Cancer Manag Res. 2019;11:379-388. [PMID: 30643463 DOI: 10.2147/cmar.s157156] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 5.0] [Reference Citation Analysis]
39 Demols A, Borbath I, Van den Eynde M, Houbiers G, Peeters M, Marechal R, Delaunoit T, Goemine JC, Laurent S, Holbrechts S, Paesmans M, Van Laethem JL. Regorafenib after failure of gemcitabine and platinum-based chemotherapy for locally advanced/metastatic biliary tumors: REACHIN, a randomized, double-blind, phase II trial. Ann Oncol 2020;31:1169-77. [PMID: 32464280 DOI: 10.1016/j.annonc.2020.05.018] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 11.0] [Reference Citation Analysis]
40 Tella SH, Kommalapati A, Borad MJ, Mahipal A. Second-line therapies in advanced biliary tract cancers. The Lancet Oncology 2020;21:e29-41. [DOI: 10.1016/s1470-2045(19)30733-8] [Cited by in Crossref: 29] [Cited by in F6Publishing: 17] [Article Influence: 14.5] [Reference Citation Analysis]
41 Saeed A, Park R, Al-jumayli M, Al-rajabi R, Sun W. Biologics, Immunotherapy, and Future Directions in the Treatment of Advanced Cholangiocarcinoma. Clinical Colorectal Cancer 2019;18:81-90. [DOI: 10.1016/j.clcc.2019.02.005] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 4.0] [Reference Citation Analysis]
42 Wang C, Huang M, Geng Q, Li W, Chang J, Tang W, Guo W. Apatinib for patients with metastatic biliary tract carcinoma refractory to standard chemotherapy: results from an investigator-initiated, open-label, single-arm, exploratory phase II study. Ther Adv Med Oncol 2021;13:17588359211039047. [PMID: 34484431 DOI: 10.1177/17588359211039047] [Reference Citation Analysis]
43 Bogenberger JM, DeLeon TT, Arora M, Ahn DH, Borad MJ. Emerging role of precision medicine in biliary tract cancers. NPJ Precis Oncol 2018;2:21. [PMID: 30302397 DOI: 10.1038/s41698-018-0064-z] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.5] [Reference Citation Analysis]
44 Mo HN, Liu P. Targeting MET in cancer therapy. Chronic Dis Transl Med 2017;3:148-53. [PMID: 29063069 DOI: 10.1016/j.cdtm.2017.06.002] [Cited by in Crossref: 53] [Cited by in F6Publishing: 54] [Article Influence: 10.6] [Reference Citation Analysis]
45 O'Rourke CJ, Munoz-Garrido P, Andersen JB. Molecular Targets in Cholangiocarcinoma. Hepatology 2021;73 Suppl 1:62-74. [PMID: 32304327 DOI: 10.1002/hep.31278] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
46 Leone JP, Duda DG, Hu J, Barry WT, Trippa L, Gerstner ER, Jain RK, Tan S, Lawler E, Winer EP, Lin NU, Tolaney SM. A phase II study of cabozantinib alone or in combination with trastuzumab in breast cancer patients with brain metastases. Breast Cancer Res Treat 2020;179:113-23. [PMID: 31541381 DOI: 10.1007/s10549-019-05445-z] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
47 DeLeon TT, Ahn DH, Bogenberger JM, Anastasiadis PZ, Arora M, Ramanathan RK, Aqel BA, Vasmatzis G, Truty MJ, Oklu R, Bekaii-Saab TS, Borad MJ. Novel targeted therapy strategies for biliary tract cancers and hepatocellular carcinoma. Future Oncol 2018;14:553-66. [PMID: 29460642 DOI: 10.2217/fon-2017-0451] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.8] [Reference Citation Analysis]
48 Sarkis Y, Al Soueidy A, Kourie HR. Will advanced cholangiocarcinoma become a targetable malignancy? Crit Rev Oncol Hematol 2021;159:103233. [PMID: 33482346 DOI: 10.1016/j.critrevonc.2021.103233] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
49 Rahnemai-Azar AA, Pawlik TM. Cholangiocarcinoma: shedding light on the most promising drugs in clinical development. Expert Opin Investig Drugs 2021;30:419-27. [PMID: 33645382 DOI: 10.1080/13543784.2021.1897103] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
50 Athauda A, Fong C, Lau DK, Javle M, Abou-Alfa GK, Morizane C, Steward K, Chau I. Broadening the therapeutic horizon of advanced biliary tract cancer through molecular characterisation. Cancer Treat Rev 2020;86:101998. [PMID: 32203843 DOI: 10.1016/j.ctrv.2020.101998] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 6.0] [Reference Citation Analysis]
51 Sonpavde GP, Pond GR, Fizazi K, de Bono JS, Basch EM, Scher HI, Smith MR. Cabozantinib for Progressive Metastatic Castration-resistant Prostate Cancer Following Docetaxel: Combined Analysis of Two Phase 3 Trials. Eur Urol Oncol 2020;3:540-3. [PMID: 31412002 DOI: 10.1016/j.euo.2018.11.006] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
52 Merz V, Zecchetto C, Melisi D. Pemigatinib, a potent inhibitor of FGFRs for the treatment of cholangiocarcinoma. Future Oncology 2021;17:389-402. [DOI: 10.2217/fon-2020-0726] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
53 Moosavi F, Giovannetti E, Peters GJ, Firuzi O. Combination of HGF/MET-targeting agents and other therapeutic strategies in cancer. Crit Rev Oncol Hematol 2021;160:103234. [PMID: 33497758 DOI: 10.1016/j.critrevonc.2021.103234] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
54 Sun JM, Xu HT, Zhao L, Zhang YB, Kang PC, Song ZF, Liu HS, Cui YF. Induction of cell-cycle arrest and apoptosis in human cholangiocarcinoma cells by pristimerin. J Cell Biochem 2019. [PMID: 30825242 DOI: 10.1002/jcb.28485] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]